What was the primary driver of Johnson & Johnson's sales growth in the second quarter of 2006?

Johnson & Johnson's sales growth in the second quarter of 2006 was driven by a combination of factors across its business segments. The Pharmaceutical segment saw strong performance from products like RISPERDAL(R)/RISPERDAL(R) CONSTA(R), REMICADE(R), and TOPAMAX(R). The Medical Devices and Diagnostics segment was boosted by the CYPHER(R) Sirolimus-eluting Stent, Biosense Webster, and the endovascular business. The Consumer segment also contributed with strong sales in Skin Care and Baby & Kids Care.

How did the company manage its expenses, and what was the impact on profitability?

Johnson & Johnson demonstrated effective expense management, with consolidated selling, marketing, and administrative expenses as a percentage of sales decreasing in both the second quarter and the first six months of 2006 compared to the prior year. This was primarily attributed to cost containment efforts. Despite increased R&D spending, the company saw a significant rise in net earnings, indicating that revenue growth and cost efficiencies outpaced the increased investment in research and development.

What is the company's stance on its ongoing legal proceedings and potential risks from generic competition?

Johnson & Johnson acknowledges numerous ongoing legal proceedings, including product liability cases, patent litigation, and government investigations. The company states it is vigorously defending against these claims and believes its existing accruals and insurance coverage are adequate. Regarding generic competition, the company is actively defending its patents against Abbreviated New Drug Applications (ANDAs) and anticipates that success in these defenses is crucial to avoid substantial market share and revenue losses for key pharmaceutical products.

How is the company returning value to shareholders, and what is the outlook for dividends?

Johnson & Johnson is actively returning value to shareholders through both dividends and share repurchases. The company declared a regular cash dividend of $0.375 per share for the second quarter of 2006, marking the 44th consecutive year of cash dividend increases, and expects to continue this practice. Additionally, the company significantly increased its stock repurchase program, utilizing $2.7 billion for buybacks in the first six months of 2006.

JNJ 10-Q Quarterly Report Q3 FY2006 — Revenue, Net Income, EPS

Summary

Johnson & Johnson reported solid top-line growth in the second quarter of 2006, with worldwide sales increasing by 4.7% to $13.4 billion. This growth was driven by a 4.8% operational increase, indicating strong performance across its diverse business segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics. The company also saw an increase in net earnings, up 8.9% to $2.82 billion for the quarter, demonstrating effective cost management and a favorable product mix. Key financial highlights include a robust increase in operating profit for the Pharmaceutical segment, up 11.4% year-over-year, and continued strong performance in the Medical Devices and Diagnostics segment, which saw a 5.2% operating profit increase. The company also returned significant value to shareholders through dividends and share repurchases, underscoring its financial strength and commitment to shareholder returns. Despite ongoing legal proceedings and the potential impact of generic competition, Johnson & Johnson's diversified business model and strategic acquisitions continue to support its growth trajectory.

Key Highlights

1Worldwide sales grew 4.7% to $13.4 billion in the second quarter of 2006, with a 4.8% operational increase, indicating broad-based growth across segments.
2Net earnings increased by 8.9% to $2.82 billion for the quarter, demonstrating effective cost management and operational efficiencies.
3The Pharmaceutical segment showed strong operating profit growth of 11.4% year-over-year, driven by key products like RISPERDAL(R) and REMICADE(R).
4The Medical Devices and Diagnostics segment also reported a healthy operating profit increase of 5.2%, with the CYPHER(R) Sirolimus-eluting Stent being a key growth driver.
5The company significantly increased its share repurchase activity, utilizing $2.7 billion in the first six months of 2006, alongside consistent dividend payments.
6Research and development expenses increased by 19.9% in the quarter, reflecting ongoing investment in innovation and new product development, including a notable payment for Hepatitis C drug rights.

JOHNSON & JOHNSON Quarterly Report for Q3 Ended Jul 2, 2006

Summary

Key Highlights

Frequently Asked Questions